FDA
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Provides Nomlabofusp Development Update
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Wedbush Starts Larimar Therapeutics (LRMR) at Outperform
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

